{
    "Trade/Device Name(s)": [
        "Dimension Vista\u2122M Creatine Kinase MB Isoenzyme (CKMB) Flex\u00ae reagent cartridge",
        "Dimension VistaTM Hemoglobin A1c Kit (HA1C)",
        "Dimension Vista\u2122M Urine Amphetamine/Methamphetamine Screen (AMPH) Flex\u00ae reagent cartridge",
        "Dimension VistaTM Urine Barbiturates Screen (BARB) Flex\u00ae reagent cartridge",
        "Dimension VistaTM Urine Benzodiazepines Screen (BENZ) Flex\u00ae reagent cartridge",
        "Dimension VistaTM Urine Cocaine metabolite Screen (COC) Flex\u00ae reagent cartridge",
        "Dimension VistaTM Urine Ecstasy Screen (EXTC) Flex\u00ae reagent cartridge",
        "Dimension VistaTM Urine Methadone Screen (METH) Flex\u00ae reagent cartridge",
        "Dimension VistaTM Urine Opiates Screen (OPI) Flex\u00ae reagent cartridge",
        "Dimension VistaTM Urine Phencyclidine Screen (PCP) Flex\u00ae reagent cartridge",
        "Dimension VistaTM Urine Cannabinoids Screen (THC) Flex\u00ae reagent cartridge"
    ],
    "Submitter Information": "Dade Behring Inc.",
    "510(k) Number": "K062128",
    "Predicate Device Reference 510(k) Number(s)": [
        "K943024",
        "K011852",
        "K040133",
        "K000459",
        "K000458",
        "K033713",
        "K053337",
        "K000466",
        "K003209",
        "K000462",
        "K000461"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JHS",
        "LCP",
        "DKZ",
        "DIS",
        "JXM",
        "DIO",
        "DJR",
        "DJG",
        "LCM",
        "LDJ"
    ],
    "Summary Letter Date": "July 25, 2006",
    "Summary Letter Received Date": "July 26, 2006",
    "Submission Date": "July 25, 2006",
    "Regulation Number(s)": [
        "21CFR862.1215",
        "21CFR864.7470",
        "21CFR862.3100",
        "21CFR862.3150",
        "21CFR862.3170",
        "21CFR862.3250",
        "21CFR862.3620",
        "21CFR862.3650",
        "21CFR862.3870"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system",
        "Glycosylated hemoglobin test system",
        "Amphetamine test system",
        "Barbiturate test system",
        "Benzodiazepine test system",
        "Cocaine and metabolite test system",
        "Methadone test system",
        "Opiate test system",
        "Phencyclidine test system",
        "Cannabinoid test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "tdm",
        "toxicology"
    ],
    "Analyte(s)": [
        "Creatine kinase MB isoenzyme",
        "Hemoglobin A1c (HbA1c)",
        "Amphetamines",
        "Barbiturates",
        "Benzodiazepines",
        "Benzoylecgonine (cocaine metabolite)",
        "Methylenedioxymethamphetamine (MDMA) and related drugs",
        "Methadone",
        "Opiates",
        "Phencyclidine",
        "Cannabinoids"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Whole Blood",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dimension Vista\u2122 Integrated system"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme Immunoassay",
        "Differential Rate Kinetic Method (CKMB)"
    ],
    "Methodologies": [
        "Quantitative measurement",
        "Qualitative measurement",
        "Semi-quantitative measurement"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Kit",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Dimension Vista\u2122 Flex\u00ae reagent cartridges and HA1C kit for clinical chemistry and drugs of abuse assays on the Dimension Vista\u2122 Integrated system",
    "Indications for Use Summary": "In vitro diagnostic reagents for measurement or screening of CKMB in serum/plasma, HbA1c in whole blood, and amphetamines, barbiturates, benzodiazepines, cocaine metabolite, ecstasy, methadone, opiates, phencyclidine, and cannabinoids in urine, for diagnosis, monitoring, or treatment guidance",
    "fda_folder": "Clinical Chemistry"
}